Literature DB >> 8521809

A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses.

D Rapaport1, M Ovadia, Y Shai.   

Abstract

A series of peptides derived from three domains within the fusion protein of Sendai virus was synthesized and examined for their potential to inhibit the fusion of the virus with human red blood cells. These domains include the 'fusion peptide' and two heptad repeats, one adjacent to the fusion peptide (SV-163) and the other to the transmembrane domain (SV-473). Of all the peptides tested, only SV-473 was highly inhibitive. Using fluorescently-labelled peptides, the mechanism through which the SV-473 peptide inhibits the haemolytic activity of the virus was investigated. The results suggest that interactions of the active peptide with virion elements and lipid membranes are involved. Since it has recently been found that synthetic peptides corresponding to putative coiled-coil domains of the human immunodeficiency virus (HIV) type 1 transmembrane protein gp41 are potent inhibitors of HIV, we discuss the general property of virus-derived coiled-coil peptides as inhibitors of viral infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521809      PMCID: PMC394666          DOI: 10.1002/j.1460-2075.1995.tb00239.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  42 in total

1.  Inhibition of Sendai virus by various snake venom.

Authors:  G Borkow; M Ovadia
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

2.  A leucine zipper structure present in the measles virus fusion protein is not required for its tetramerization but is essential for fusion.

Authors:  R Buckland; E Malvoisin; P Beauverger; F Wild
Journal:  J Gen Virol       Date:  1992-07       Impact factor: 3.891

3.  Sequence determination of the Sendai virus fusion protein gene.

Authors:  B M Blumberg; C Giorgi; K Rose; D Kolakofsky
Journal:  J Gen Virol       Date:  1985-02       Impact factor: 3.891

4.  Membrane fusion activity of influenza virus. Effects of gangliosides and negatively charged phospholipids in target liposomes.

Authors:  T Stegmann; S Nir; J Wilschut
Journal:  Biochemistry       Date:  1989-02-21       Impact factor: 3.162

Review 5.  The structure and function of the hemagglutinin membrane glycoprotein of influenza virus.

Authors:  D C Wiley; J J Skehel
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

6.  The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure.

Authors:  C Wild; T Greenwell; D Shugars; L Rimsky-Clarke; T Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  1995-03       Impact factor: 2.205

7.  Channel formation properties of synthetic pardaxin and analogues.

Authors:  Y Shai; D Bach; A Yanovsky
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

8.  Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes.

Authors:  Y Pouny; D Rapaport; A Mor; P Nicolas; Y Shai
Journal:  Biochemistry       Date:  1992-12-15       Impact factor: 3.162

9.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Studies on the mechanism of membrane fusion: site-specific mutagenesis of the hemagglutinin of influenza virus.

Authors:  M J Gething; R W Doms; D York; J White
Journal:  J Cell Biol       Date:  1986-01       Impact factor: 10.539

View more
  87 in total

1.  The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil.

Authors:  J M Matthews; T F Young; S P Tucker; J P Mackay
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Functional importance of the coiled-coil of the Ebola virus glycoprotein.

Authors:  S Watanabe; A Takada; T Watanabe; H Ito; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Mutations in the fusion peptide and adjacent heptad repeat inhibit folding or activity of the Newcastle disease virus fusion protein.

Authors:  T A Sergel; L W McGinnes; T G Morrison
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.

Authors:  Zhonghua Liu; Mei Shan; Li Li; Lu Lu; Shu Meng; Cheng Chen; Yuxian He; Shibo Jiang; Linqi Zhang
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

5.  The 3D structure of the fusion primed Sendai F-protein determined by electron cryomicroscopy.

Authors:  Kai Ludwig; Bolormaa Baljinnyam; Andreas Herrmann; Christoph Böttcher
Journal:  EMBO J       Date:  2003-08-01       Impact factor: 11.598

6.  Protein grafting of an HIV-1-inhibiting epitope.

Authors:  Samuel K Sia; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

7.  Side chain packing below the fusion peptide strongly modulates triggering of the Hendra virus F protein.

Authors:  Everett Clinton Smith; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

8.  Inhibition of hendra virus fusion.

Authors:  M Porotto; L Doctor; P Carta; M Fornabaio; O Greengard; G E Kellogg; A Moscona
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

9.  Interacting domains of the HN and F proteins of newcastle disease virus.

Authors:  Kathryn A Gravel; Trudy G Morrison
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein.

Authors:  Dirk Roymans; Hendrik L De Bondt; Eric Arnoult; Peggy Geluykens; Tom Gevers; Marcia Van Ginderen; Nick Verheyen; Hidong Kim; Rudy Willebrords; Jean-François Bonfanti; Wouter Bruinzeel; Maxwell D Cummings; Herman van Vlijmen; Koen Andries
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.